

FISCAL NOTE

HB 1853 - SB 2038

March 26, 2007

SUMMARY OF BILL: Establishes Soma (Carisoprodol) and Ultram (Tramadol) as Schedule IV controlled substances. Requires anyone purchasing a scheduled controlled substance to provide government issued identification and sign a log at the point of sale.

ESTIMATED FISCAL IMPACT:

Increase State Expenditures – Not Significant
Increase State Revenues – Not Significant

Assumptions:

- The Board of Pharmacy will be responsible for disciplinary action against pharmacies, pharmacists, and pharmacy technicians who violate the provisions of the bill. Such will not result in a significant increase in expenditures.
- The Board of Pharmacy, by statute, is self-supporting such that revenues equal expenditures.

CERTIFICATION:

This is to duly certify that the information contained herein is true and correct to the best of my knowledge.

A handwritten signature in black ink, appearing to read "James W. White".

James W. White, Executive Director

HB 1853 - SB 2038